Back to Search
Start Over
Identifying antimalarial compounds targeting dihydrofolate reductase-thymidylate synthase (DHFR-TS) by chemogenomic profiling.
- Source :
-
International journal for parasitology [Int J Parasitol] 2016 Jul; Vol. 46 (8), pp. 527-35. Date of Electronic Publication: 2016 May 02. - Publication Year :
- 2016
-
Abstract
- The mode of action of many antimalarial drugs is unknown. Chemogenomic profiling is a powerful method to address this issue. This experimental approach entails disruption of gene function and phenotypic screening for changes in sensitivity to bioactive compounds. Here, we describe the application of reverse genetics for chemogenomic profiling in Plasmodium. Plasmodium falciparum parasites harbouring a transgenic insertion of the glmS ribozyme downstream of the dihydrofolate reductase-thymidylate synthase (DHFR-TS) gene were used for chemogenomic profiling of antimalarial compounds to identify those which target DHFR-TS. DHFR-TS expression can be attenuated by exposing parasites to glucosamine. Parasites with attenuated DHFR-TS expression were significantly more sensitive to antifolate drugs known to target DHFR-TS. In contrast, no change in sensitivity to other antimalarial drugs with different modes of action was observed. Chemogenomic profiling was performed using the Medicines for Malaria Venture (Switzerland) Malaria Box compound library, and two compounds were identified as novel DHFR-TS inhibitors. We also tested the glmS ribozyme in Plasmodium berghei, a rodent malaria parasite. The expression of reporter genes with downstream glmS ribozyme could be attenuated in transgenic parasites comparable with that obtained in P. falciparum. The chemogenomic profiling method was applied in a P. berghei line expressing a pyrimethamine-resistant Toxoplasma gondii DHFR-TS reporter gene under glmS ribozyme control. Parasites with attenuated expression of this gene were significantly sensitised to antifolates targeting DHFR-TS, but not other drugs with different modes of action. In conclusion, these data show that the glmS ribozyme reverse genetic tool can be applied for identifying primary targets of antimalarial compounds in human and rodent malaria parasites.<br /> (Copyright © 2016 Australian Society for Parasitology. Published by Elsevier Ltd. All rights reserved.)
- Subjects :
- Animals
Dose-Response Relationship, Drug
Erythrocytes parasitology
Female
Gene Expression
Humans
Inhibitory Concentration 50
Mice
Mice, Inbred BALB C
Organisms, Genetically Modified
Plasmids
Plasmodium berghei enzymology
Plasmodium berghei genetics
Plasmodium falciparum enzymology
Plasmodium falciparum genetics
RNA, Catalytic drug effects
Specific Pathogen-Free Organisms
Tetrahydrofolate Dehydrogenase genetics
Tetrahydrofolate Dehydrogenase metabolism
Thymidylate Synthase antagonists & inhibitors
Thymidylate Synthase genetics
Thymidylate Synthase metabolism
Transfection
Antimalarials pharmacology
Folic Acid Antagonists pharmacology
Plasmodium berghei drug effects
Plasmodium falciparum drug effects
Tetrahydrofolate Dehydrogenase drug effects
Thymidylate Synthase drug effects
Subjects
Details
- Language :
- English
- ISSN :
- 1879-0135
- Volume :
- 46
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- International journal for parasitology
- Publication Type :
- Academic Journal
- Accession number :
- 27150044
- Full Text :
- https://doi.org/10.1016/j.ijpara.2016.04.002